Mark Chasin

Title: Mark Chasin: Innovator in Controlled Release Technology

Introduction

Mark Chasin is an accomplished inventor based in Englishtown, NJ (US). He is known for his significant contributions to the field of controlled release technology, particularly in the development of bioerodible implants. His innovative work has the potential to enhance the administration of biologically active compounds, making a notable impact in the medical field.

Latest Patents

Mark Chasin holds 1 patent for his invention titled "Polyanhydride bioerodible controlled release implants for administration." This patent describes a controlled release device designed for the administration of biologically active growth hormone proteins or peptide fragments. The method of preparation involves stabilizing the growth hormone and modulating the release rate by incorporating a stabilizing compound. The devices are created by mixing a stabilizer, such as sucrose, with the growth hormone in solution, followed by lyophilization. The resulting dried powder is then incorporated into a surface erodible, biocompatible polymeric matrix, such as a poly(anhydride) or poly(orthoester) matrix.

Career Highlights

Throughout his career, Mark Chasin has worked with notable organizations, including Nova Pharmaceutical Corporation and the Massachusetts Institute of Technology. His experience in these institutions has allowed him to refine his expertise in pharmaceutical technology and innovation.

Collaborations

Mark has collaborated with esteemed colleagues such as Eyal S Ron and Tom Turek. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Mark Chasin's work in controlled release technology exemplifies the innovative spirit of modern inventors. His contributions have the potential to significantly improve the delivery of biologically active compounds, paving the way for advancements in medical treatments.